
    
      In this single-center, open-label, nonrandomized, no control, prospective clinical trial,
      appoximately 15 relapsed or refractory B-cell lymphoma patients will be enrolled. Side
      effects of CD19 CAR T cells therapy will be monitored. The purpose of current study is to
      determine the clinical efficacy and safety of CD19 CAR T cells therapy in patients with R/R
      B-cell lymphoma
    
  